Danaher Corporation

Over 80% of FY2025 sales are consumables and services, providing substantial forward visibility against an installed base across biopharma, hospital, and research lab settings. The FY2023-FY2024 bioprocessing destocking cycle revealed that even the consumables base can experience meaningful 12-18 month inventory-driven demand troughs when customers over-purchase during unusual demand spikes.

Danaher operates three segments (biotechnology, life sciences, diagnostics) serving different end markets, customers, and purchasing cycles that provide partial offset during sector-specific downturns. Bioprocessing via Cytiva represents the largest single concentration within the portfolio, though the three segments have genuinely uncorrelated demand drivers.

FY2024 revenue was split across North America (roughly 42%), other developed markets including Western Europe (roughly 46%), and China (roughly 12%, representing $2.81B). No single country exceeds 40%, and the spread provides meaningful diversification, though China's concentration creates material exposure to trade and regulatory policy shifts.

The Danaher Business System drives continuous margin improvement, and the 80%-plus consumables mix generates favorable unit economics as the installed base expands. Adjusted operating margin reached approximately 28% in FY2025, supported by $250M in cost actions, though ongoing manufacturing, R&D, and field service infrastructure limits the degree of incremental operating leverage.

More than 80% of FY2025 revenue comes from consumables and services, including bioprocessing resins and cell culture media essential to every biologic drug manufacturing process, and diagnostic reagents tied to hospital analyzer fleets. This mission-critical, non-discretionary revenue profile has been sustained as the structural revenue mix across FY2021-FY2025.